Description

Irinotecan Amaxa Concentrate for Infusions 20 mg/ml. 15 ml. (300 mg.) №1

Ingredients:

Each ml contains 20 mg of Irinotecan hydrochloride trihydrate as the active ingredient.

Dosage:

The recommended dosage of Irinotecan Amaxa concentrate for infusions is determined by the patient’s body surface area and overall health condition.

Indications:

Irinotecan Amaxa concentrate for infusions is indicated for the treatment of colorectal cancer and small cell lung cancer.

Contraindications:

This medication is contraindicated in patients with a known hypersensitivity to Irinotecan or any of the excipients in the formulation.

Directions:

Irinotecan Amaxa concentrate for infusions should be administered intravenously by a healthcare professional experienced in cancer chemotherapy.

Scientific Evidence:

Irinotecan has demonstrated efficacy in the treatment of various cancers through its ability to inhibit topoisomerase I, leading to DNA damage and cell death.

Clinical trials have shown that Irinotecan, when used in combination with other chemotherapeutic agents, can improve overall survival rates in cancer patients.

Additional Information:

It is important to monitor patients receiving Irinotecan for potential side effects such as diarrhea, neutropenia, and nausea.

Patients should be informed about the potential risks and benefits of Irinotecan therapy before starting treatment.